Previous close | 8.00 |
Open | 8.00 |
Bid | 5.90 |
Ask | 10.00 |
Strike | 100.00 |
Expiry date | 2025-01-17 |
Day's range | 8.00 - 8.00 |
Contract range | N/A |
Volume | |
Open interest | 68 |
The FDA has undertaken an investigation of T-cell malignancies in patients undergoing CAR T-cell therapy treatment. Therapies from NVS, BMY and GILD are under the spotlight.
Novartis (NVS) increases its sales guidance for the mid-term (2022-2027) and outlines its growth strategy as a pure-play pharmaceutical company.
It is tempting to celebrate big milestones. Novartis chief Vas Narasimhan can be forgiven for doing so. His focus is on higher-margin, innovative drugs. The Swiss group is a cleaner proposition after spinning off its generics business Sandoz in October.